Compare HDSN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDSN | RCKT |
|---|---|---|
| Founded | 1991 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.0M | 277.7M |
| IPO Year | 1996 | 2014 |
| Metric | HDSN | RCKT |
|---|---|---|
| Price | $4.41 | $2.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $5.75 | ★ $8.58 |
| AVG Volume (30 Days) | 622.4K | ★ 1.6M |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | 0.17 | ★ 0.23 |
| Revenue | ★ $237,118,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.68 | $1,102.46 |
| P/E Ratio | $26.06 | ★ $3.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.03 | $2.17 |
| 52 Week High | $7.74 | $5.45 |
| Indicator | HDSN | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 38.03 | 41.72 |
| Support Level | $4.03 | $2.23 |
| Resistance Level | $6.47 | $2.73 |
| Average True Range (ATR) | 0.20 | 0.19 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 27.73 | 24.84 |
Hudson Technologies Inc is a refrigerant services company providing solutions to recurring challenges within the refrigeration industry. The company delivers environmentally sustainable offerings, covering the sale of refrigerant gases, recovery, reclamation, and reuse, as well as improving equipment performance through energy efficiency services, emergency air conditioning and refrigeration system repairs, refrigerant disposal, and carbon credit trading. It operates through one reportable segment. Its products and services are used in commercial air conditioning, industrial processing, and refrigeration systems, and include refrigerant and industrial gas sales, refrigerant management services (mainly reclamation of refrigerants), and RefrigerantSide services performed at customer sites.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.